跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
CD7 targeted CAR-T
首页
药物
CD7 targeted CAR-T
CD7 targeted CAR-T
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Universal CAR-T targeting CD5 and CD7 and application thereof
CN 117467707 A
申请人: SHANGHAI XUNLU BIO TECH CO LTD
优先权: 2022
CN
2 件公开
Antibody targeting human CD7 or antigen binding fragment thereof and application thereof
CN 117362437 A
申请人: NANJING PENGBO BIOTECHNOLOGY CO LTD
优先权: 2023
CN
2 件公开
T-CELL ANTIGEN TARGETED CHIMERIC ANTIGEN RECEPTOR (CAR) AND USES IN CELL THERAPIES
CN 110944652 A
申请人: UNIV EMORY
优先权: 2017
CN
CD7-targeted engineered immune cell, chimeric antigen receptor, CD7 blocking molecule and application
CN 115947852 A
申请人: SHANGHAI YAKE BIOLOGICAL SCIENCE & TECH CO LTD
优先权: 2021
CN
Bispecific universal CAR-T cell capable of simultaneously targeting CD7 and CD19 and preparation method of bispecific universal CAR-T cell
CN 114369622 A
申请人: XIAN MULBERRY NISI CELL BIOMEDICINE CO LTD
优先权: 2021
CN
Anti-CD7 nano antibody as well as related product and application thereof
CN 120005024 A
申请人: HEBEI SENLANG BIOTECHNOLOGY CO LTD
优先权: 2022
CN
Method for modifying endogenous CD7 gene of cell and application thereof
CN 119242715 A
申请人: CHENGDU YOUSAINUO BIOTECHNOLOGY CO LTD
优先权: 2024
CN
无电转、批量制备免疫细胞治疗产品的方法及其产品
CN 120866421 B
申请人: 深圳细胞谷生物医药有限公司
优先权: 2025
CN
药物
反馈